[{"from": "human", "value": "Describe this molecule. [C][C@H1][Branch2][Ring1][#Branch2][C][=Branch1][C][=O][N][C@H1][Branch1][Ring1][C][O][C][=C][C][=Branch1][=Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][O][C][N][C][C][=C][Branch1][Branch1][C][Ring1][Branch1][=O][C][=C][Branch1][Branch1][C][=C][Ring1][Branch2][C][=N][C][=Branch1][#Branch1][=N][C][=C][Ring1][=Branch1][Cl][N][C][C][C][O][C][C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, ASTX029 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells."}]